Paxmedica, Inc. · OTC:PXMD

Paxmedica — Investor Presentation (March 2024)

17 slides from Paxmedica's investor presentation, Mar 13, 2024

1. Slide 1: PXMD Investor Presentation February 2024

   PXMD Investor Presentation February 2024 © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3

2. Slide 2: Forward-Looking Statements

   © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 2 Forward - Looking Statements This Presentation contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions,

3. Slide 3: The Challenge and The Path To Treat Core Symptoms of ASD: 2024-'27

   © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 3 THE CHALLENGE • Over 3.5 million people in the U.S. with Autism Spectrum Disorder (ASD) • Adult ASD population lacks targeted pharmacologic therapies • No existing FDA - approved medications to treat ASD core symptoms THE IMP

4. Slide 4: A Pipeline of Anti-Purinergic Compounds

   © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 4 A Pipeline of Anti - Purinergic Compounds

5. Slide 5: Forging a New Path in ASD Treatment

   © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 5 PAX - 101 Phase 2 Clinical Trial in ASD FORGING A NEW PATH IN ASD TREATMENT

6. Slide 6: Normal physiological response vs pathological response in autism

   © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v2.0 © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v2.0 © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 6 In typical immune mediated biological mechanisms, cellular response to pote

7. Slide 7: Proposed Mechanism of Action: Targeting Purine Receptors to Mitigate ASD Symptoms

   © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 7 7 PROPOSED PAX - 101 MECHANISM OF ACTION » PAX - 101 (intravenous suramin) selectively block s purine (P2) receptors which regulate immune responses via extracellular ATP based signal pathways. » By selectively and reversibly

8. Slide 8: Positive Shifts in Behavior: Impact on ASD Symptoms

   © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 8 Positive Shifts in Behavior: PAX - 101 Impact on ASD Symptoms Substantial Reduction in ABC Subscale Scores Demonstrates PAX - 101 Efficacy Over 14 Weeks -15 -13 -11 -9 -7 -5 -3 -1 1 ABC-I (Irritability) ABC-II (Social Withdra

9. Slide 9: Key Takeaways

   © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 9 KEY TAKEAWAYS • Both dosage regimens showed improved baseline ASD symptoms • 10 mg/kg dosage resulted in a statistically significant and meaningful change on the ABC scale • Larger - scale studies planned for further validati

10. Slide 10: Dose-Dependent Improvement

    © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 10 DOSE - DEPENDENT IMPROVEMENT Both PAX - 101 dosage levels significantly improved core ASD symptoms, showcasing the drug's effectiveness. CLINICALLY SIGNIFICANT OUTCOMES The 10 mg/kg dosage cohort exhibited a substantial and

11. Slide 11: HAT NDA Submission Plan

    © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 11 PAX - 101 for HAT NDA SUBMISSION PLAN

12. Slide 12: NDA Submission Pathway: Expanding ASD Treatment

    © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 12 • Upon NDA approval, anticipate obtaining a valuable PRV • PRV asset potential monetization creates the runway for ASD and other clinical trials • 505(b)(2) NDA planned for 2024, leveraging existing data for efficiency • Poi

13. Slide 13: Study Overview

    © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 Study Overview KEY RESULTS • 94% survival and treatment completion in the suramin - treated cohort • Benchmarking: Comparative group's outcomes, with a significant portion facing severe health risks RESEARCH METHODOLOGY • Retro

14. Slide 14: Strong Financial Position

    © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 Strong Financial Position • $4.7M in cash reserves as of December 31, 2023 • Access to additional $14.6M in funding through Lincoln Park Capital equity line of credit Capital Performance • 7.4M shares of Common Stock currently

15. Slide 15: Advancing Neurological Disorder Treatments

    © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 15 Advancing Neurological Disorder Treatments Progressing Towards ASD Treatment PAX - 101, an innovative product candidate for ASD core symptoms Strategic Regulatory Milestone ASD Focus Leadership Excellence PaxMedica, the publ

16. Slide 16: Management Team and Board of Directors

    © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 Management Team Led by Experienced Pharma Entrepreneurs Howard J. Weisman Chief Executive Officer Stephen Sheldon Chief Operating/Financial Officer Buzz Woods Corporate Communications Dr. David Hough Chief Medical Officer Stron

17. Slide 17: Thank You

    © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 17 THANK YOU For More Information Contact: B u zz Woods PaxMedica Corporate Communications bwoods@paxmedica.com Scott McGowen IBN (InvestorBrandNetwork) scott.mcgown@investorbrandnetwork.com (402) 681 - 1025 WWW.PAXMEDICA.COM

PaxMedica — Investor Presentation (March 2024) on 6ix